FDC Ltd (FDC)
₹412.95
Mkt cap
₹6,723 Cr
P/E ratio
22.60
P/B
2.70
Div yield
1.21%
ROE
12.50%
ROCE
16.70%
EPS (TTM)
₹18.27
Book value
₹153
52W range
321–491
Sector
Healthcare
FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets. [1]
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−15.81% from high₹413
₹321+28.60% from low₹491
Current
₹412.95
Prev close
₹415.00
Day
−0.49%
Price performance
1D
−0.49%
1W
−1.18%
1M
+1.14%
3M
+12.78%
6M
+8.05%
1Y
−17.21%
YTD
−1.57%
Financials
FRevenue, profit & margin
P/E ratio
22.6×
FDC is 34% below the sector median of 34.0×
FDC22.6×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 435 | 536 | 486 | 458 | 462 | 638 | 514 | 464 | 492 | 648 | 473 | 465 | 585 | |
| Expenses | 386 | 414 | 410 | 374 | 406 | 492 | 444 | 417 | 438 | 508 | 439 | 412 | 478 | |
| Operating Profit | 49 | 122 | 76 | 84 | 56 | 147 | 70 | 47 | 54 | 140 | 34 | 52 | 106 | |
| OPM % | 11% | 23% | 16% | 18% | 12% | 23% | 14% | 10% | 11% | 22% | 7% | 11% | 18% | |
| Other Income | 7 | 29 | 27 | 25 | 20 | 28 | 35 | 19 | 16 | 36 | 21 | 0 | 50 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 11 | 14 | 13 | 16 | 15 | 15 | 15 | 14 | |
| Profit before tax | 45 | 141 | 93 | 98 | 65 | 163 | 90 | 51 | 53 | 160 | 38 | 36 | 140 | |
| Tax % | 32% | 22% | 25% | 19% | 29% | 27% | 20% | 28% | 27% | 24% | 26% | 22% | 26% | |
| Net Profit | 31 | 110 | 70 | 79 | 46 | 119 | 72 | 37 | 39 | 121 | 28 | 28 | 103 | |
| EPS in Rs | 1.85 | 6.62 | 4.29 | 4.87 | 2.84 | 7.31 | 4.42 | 2.28 | 2.38 | 7.45 | 1.74 | 1.74 | 6.35 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
5 Aug '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202669.65%Promoter
Promoters69.65%
FIIs1.40%1.00
DIIs6.31%0.02
Public22.63%0.98
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| FDC | ₹412.95 | 22.63 | 6,723 | 1.21% | 103 | +167.39% | 585 | +18.89% | 16.67% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2012nse
Concall transcripts16
Announcements5
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday, August 05, 2026. 1d - Board meeting on August 5, 2026 to approve Q1 FY27 standalone and consolidated results; trading window closed till 48 hours after results.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 JunDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 JunDisclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 JunClosure of Trading Window 26 Jun - Trading window closed from July 1, 2026 until 48 hours after Q1 results.